AstraZeneca PLC
AZN · NASDAQ
9/30/2025 | 6/30/2025 | 3/30/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $15 | $14 | $14 | $15 |
| % Growth | 5.1% | 6.4% | -8.8% | – |
| Cost of Goods Sold | $3 | $2 | $2 | $3 |
| Gross Profit | $12 | $12 | $11 | $12 |
| % Margin | 81.2% | 82.9% | 83.5% | 81.7% |
| R&D Expenses | $4 | $4 | $3 | $5 |
| G&A Expenses | $5 | $5 | $4 | $5 |
| SG&A Expenses | $5 | $5 | $5 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Expenses | $9 | $8 | $8 | $10 |
| Operating Income | $4 | $4 | $4 | $2 |
| % Margin | 23.6% | 24.3% | 27% | 13.7% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $3 | $3 | $3 | $2 |
| Tax Expense | $1 | $1 | $0 | $0 |
| Net Income | $3 | $2 | $3 | $2 |
| % Margin | 16.7% | 16.9% | 21.5% | 10.1% |
| EPS | 0.82 | 0.79 | 0.94 | 0.49 |
| % Growth | 3.8% | -16% | 91.8% | – |
| EPS Diluted | 0.81 | 0.79 | 0.94 | 0.48 |
| Weighted Avg Shares Out | 3 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 3 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $1 | $1 | $1 |
| EBITDA | $5 | $5 | $5 | $3 |
| % Margin | 33.8% | 34.3% | 37.1% | 18.9% |